Alopexx, Inc. has a Form S-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-09-09. Amendments on record here: 6. As of its latest filing, on 2026-09-17, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We have applied to have our common stock listed on the NYSE American LLC (the “NYSE American”) under the symbol “ALPX”.From the S-1/A filed 2026-09-17
Price range
We estimate that the initial public offering price of our shares will be between $10.00 and $12.00 per share.From the S-1/A filed 2026-09-17
Use of proceeds
We currently intend to use the net proceeds from this offering to advance our product candidates, fund completion of proof -of-concept clinical trials of vaccine AV0328 and monoclonal antibody F598 manufacturing scale -up activities, and for general corporate purposes, including working capital, operating expenses and capital expenditures.From the S-1/A filed 2026-09-17
Net loss or income
Our net losses were $2,608,394 and $3,060,624 for the years ended December 31, 2025 and 2024, respectively.From the S-1/A filed 2026-09-17
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-09-09 | Registration statement amended | S-1/A |
| 2025-01-08 | Registration statement amended | S-1/A |
| 2025-02-25 | Registration statement amended | S-1/A |
| 2026-06-26 | Registration statement amended | S-1/A |
| 2026-08-17 | Registration statement amended | S-1/A |
| 2026-09-17 | Registration statement amended | S-1/A |
Tools for this story
Each opens in a new tab, filled in for Alopexx, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.